Kurs kaydını izlemek için tıklayınız.

• 1. Modül Programı
• KML&MPN Ustalık Sınıfı - 1. Modül - 1. Hafta
• KML&MPN Ustalık Sınıfı - 1. Modül - 2. Hafta
• KML&MPN Ustalık Sınıfı - 1. Modül - 3. Hafta
• KML&MPN Ustalık Sınıfı - 1. Modül - 4. Hafta
• Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs
• Dasatinib-induced pulmonary arterial hypertension
• Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
• ELN 2020 CML Recommendations
• Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion
• ESMO CML Guidelines
• European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in CML
• Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
• Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemi
• Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
• Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors
• Milestones and Monitoring
• Chronic Myeloid Leukemia
• Pleural Effusion in Dasatinib-Treated Patients with CML-CP - Identification and Management
• Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia
• The Impact of BCR-ABL1 Transcript Type on TKI Responses in CML
• When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently